All Pfizer articles
-
BusinessProtein degrading breast cancer drugs navigate bumpy road to market
Camizestrant is now approved in US, UK and Europe despite uncertainty over long-term benefit, while vepdegestrant is approved in the US
-
BusinessPfizer’s green chemistry team turns 25
What began as a grassroots initiative has become embedded across Pfizer’s research and manufacturing operations, helping reshape processes from Viagra to Paxlovid
-
BusinessPfizer wins bidding war for Metsera and its weight-loss drugs
US firm matched Novo Nordisk’s rival bid and had backing of competition regulator
-
BusinessPfizer and Novo Nordisk’s battle over Metsera
Lawsuits fly in bidding war over developer of next generation weight loss drugs
-
CareersGood network connections help startup founders and employees to succeed
Career success is easier with help from others
-
CareersThe startups that grew out of the Pfizer redundancies
18 months on, three former Pfizer employees explain how they’ve seized opportunities to fill gaps in the market
-
OpinionWhy companies are rushing to flatter Trump
Pharma firms are among many pausing diversity programmes and promising domestic investment
-
-
OpinionLetters: January 2024
Readers clarify the details of Pfizer’s future plans, muse on the philosophy of assembly theory and more
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
BusinessPfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
OpinionThe shadow of drug resistance
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
BusinessPfizer sues former employee for alleged trade secret theft
Chun Xiao Li downloaded thousands of confidential documents before resigning
-
BusinessCovid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
BusinessUS grants Pfizer’s Covid-19 vaccine full approval
WHO calls for delay to booster programmes to allow more global distribution
-
BusinessPfizer backs protein degrader drugs with Arvinas deal
$1bn investment to commercialise breast cancer treatment